Formulary Search
A to Z of Drugs : G
Show Icon and Status Keys
- Capsules
- Oral solution
- Tablets
- Capsules
Off-label use.
- Not Specified
- Not Specified
- Capsules
- Oral solution
- Tablets
- Capsules
- Gel
- Intra-articular injection
- Modified release capsules
- Oral solution
Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Not Specified
- Modified release capsules
- Oral solution
In Lewy Body dementia if donepezil or rivastigmine are not tolerated / unsuitable. Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Modified release capsules
- Oral solution
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Not Specified
- Subcutaneous injection (sc)
- Infusion
- Injection
Restricted antimicrobial to be used under advice of Microbiology, GUM, HIV, Oncology Specialist
- Eye gel
- Intravitreal injection
- Subconjunctival injection
Prevention of recurrent attacks in people 12 years and over. Immunology specialist only
- Chewable tablets
- Suspension
- Sachets (powder)
- Tablets
Refractory or unexplained chronic cough
Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.
- Not Specified
- Pessaries
- Capsules
- Tablets
- Eye drops
- Subconjunctival injection
- Infusion
- Injection
- Eye drops (preservative free)
- Ear drops
- Ear drops
- Not Specified
Relapsing-remitting multiple sclerosis
- Tablets
- Tablets
- Tablets
- Modified release
- Tablets
- Tablets
- Intravenous injection (IV)
- Vials
Gluagen Hypokit (powder and solvent) only.
- Intravenous injection (IV)
Stock not held by Surrey Trusts. Available from regional centres. Refer to TOXBASE / NPIS for advice
- Not Specified
- Oral solution
Glucose 250mg per ml (75g in 300ml).
Not supplied by Pharmacy at SASH - ordered from NHS Procurement
- Oral gel
- Liquid
- Not Specified
- Suppositories
- Ointment
- Cream
- Ointment
- Sublingual spray
- Sublingual tablets
- Patches
- Injection
- Not Specified
- Inhaler (dry powder)
Second line - low resistance inhaler. With low-resistance devices, patients must inhale faster to generate the power to separate the drug molecules, which may be difficult in patients with poor lung function.
Combination with LABA recommended in COPD.
Prescribe by BRAND
- Oral solution
- Tablets
Off-label use
- Subcutaneous infusion
- Subcutaneous injection (sc)
- Oral solution
Glycopyrronium is a treatment choice after oxybutynin and propantheline if they have not been tolerated or have not been effective.
Initiation, a minimum of 1 month supply, and a review by the specialist team before transfer to primary care can be requested.
1mg/5ml oral solution sugar free.
Off-label use and much more expensive than other treatment options in primary care.
DO NOT prescribe 400mcg/ml due to high cost
- Tablets
Glycopyrronium is a treatment choice after oxybutynin and propantheline if they have not been tolerated or have not been effective.
Initiation, a minimum of 1 month supply, and a review by the specialist team before transfer to primary care can be requested.
Oral solution 1mg/5ml is the more cost-effective oral glycopyrronium. Tablets should be reserved for patients requiring high doses.
- Tablets
- Oral solution
- Tablets
- Oral solution
- Oral solution
- Powder
- Topical solution
- Injection
- Inhaler (Metered Dose)
This is the only LAMA/LABA available in an MDI device. Same cost as other LAMA/LABAs
- Inhaler (dry powder)
Second line - low-resistance device so patients must inhale faster to generate the power to separate the drug molecules, which may be difficult in patients with poor lung function.
Prescribe by BRAND
- Tablets
- Subcutaneous injection (sc)
- Subcutaneous injection (sc)
Ulcerative Colitis in Adults only. Prescribe by brand.
- Subcutaneous injection (sc)
- Subcutaneous injection (sc)
Severe disease only
- Injection
- Implant
- Pre-filled syringe
The specialist team should initiate treatment and administer the 1st injection prior to transfer of care.
- Implant
- Pre-filled syringe
The specialist team should initiate treatment and administer the 1st injection prior to transfer of care.
- Subcutaneous injection (sc)
- Implant
Primary Care prescribing appropriate on recommendation from the specialist team.
- Subcutaneous injection (sc)
- Injection
EXISTING patients only. Do not initiate in new patients.
- Injection
- Injection
- Patches
- Tablets
- Subcutaneous injection (sc)
For immunology specialist only
Allergovit - RSFT Immunology only.
- Oromucosal spray
For immunology specialist only
Oralvac Compact drops - RSFT Immunology only
- Subcutaneous injection (sc)
For immunology specialist only
Pollinex quattro - RSFT Immunology only
- Sublingual tablets
For immunology specialist only
Lais tablets (grass pollen) - RSFT immunology only
- Oral lyophilisates
- Oral lyophilisates
- Tablets
- Modified release tablets
Guanfacine for use in adult patients with ADHD (that have not transferred from children’s service on the medication), has not yet been assessed for formulary status.
National shared care documents are being considered by Surrey & Borders Partnership NHS Foundation Trust for implementation over the next few months through APC.
Adult patients currently being prescribed guanfacine in primary care can continue on treatment until they and their prescriber or specialist consider it appropriate to stop.
- Modified release tablets
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release tablets
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release tablets
Complex patients (cohort 3) = Red (will remain with the specialist service)
- Subcutaneous injection (sc)
For UC & CD. Prescribe by brand
- Intravenous injection (IV)
For UC & CD. Prescribe by brand
- Injection
Dermatology specialist team only.
- Not Specified
- Subcutaneous injection (sc)